Is Aurinia Pharmaceuticals a Buy?
There's good news and bad news for Aurinia Pharmaceuticals (NASDAQ: AUPH) shareholders. Let's start with the good news. The company has had a fantastic 2017, with its stock price soaring more than 120% year to date with less than two weeks remaining in the year.
Now for the bad news. All of those gains -- and a lot more -- came during the first few months of the year. Since late March, Aurinia has lost nearly half of its market cap. This big pullback resulted primarily from a stock offering that diluted the value of existing shares. But with a new year just around the corner, is Aurinia Pharmaceuticals a buy now?
Image source: Getty Images.
Source: Fool.com
Aurinia Pharmaceuticals Inc. Aktie
5,82 €
2,25 %
Noch kein klares Bild: Aurinia Pharmaceuticals Inc. mit nur einigen Einschätzungen.
Ein unerwartetes Potenzial von 71.94% für Aurinia Pharmaceuticals Inc., gegeben ein Kursziel von 10 €, das über dem aktuellen Kurs von 5.82 € liegt.
